Table 6.
Administration of adjuvant therapy according to treatment groups, n (%).
| Therapy | Straver et al22 |
Sávolt et al23 |
||||
|---|---|---|---|---|---|---|
| cALND (n = 300) | ART (n = 266) | P | cALND (n = 244) | ART (n = 230) | P | |
| CT | 175 (58.3) | 162 (60.9) | 0.296 | 190 (77.9) | 159 (69.1) | 0.020 |
| ET | 235 (78.3) | 203 (76.3) | 0.318 | 213 (87.3) | 204 (88.7) | 0.372 |
| CT + ET | 140 (46.7) | 123 (46.2) | 0.434 | 159 (65.2) | 133 (57.8) | 0.061 |
| Trastuzumab | – | – | – | 6 (2.5) | 13 (5.7) | 0.061 |
| RT (breast/chest wall) | 257 (85.7) | 237 (89.1) | 0.136 | 232 (95.1) | 208 (90.4) | 0.115 |
| RT (axillary/supraclavicular) | 15 (5.0) | 266 (100) | 0.000 | 76 (31.1) | 230 (100) | 0.000 |
cALND: complete axillary lymph node dissection; ART: axillary radiotherapy; CT: chemotherapy; ET: endocrine therapy; RT: radiotherapy. –: not applicable.
Note: In the study of Straver et al,22 information about the adjuvant treatment is missing in 7 patients; 23 and 24 patients did not receive CT or ET in the cALND and ART group, respectively.